India, April 8 -- Shares of KalVista Pharmaceuticals, Inc. (KALV) were gaining around 5 percent in the pre-market activity on the Nasdaq, after the company announced Tuesday that its unit, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (KKPCF) for sebetralstat.
KalVista's lead investigational product sebetralstat is a novel, oral, on-demand treatment for hereditary angioedema or HAE.
Under the deal, KalVista will receive an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement of a regulatory milestone anticipated in early 2026.
Beyond these payments, the company is also eligible for commercial milestone payments, plus royalties ...